Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes
NCT ID: NCT02551315
Last Updated: 2022-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
274 participants
OBSERVATIONAL
2016-06-30
2020-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 2 diabetics, no fractures
Postmenopausal women and men with T2DM, without prevalent fragility fractures (longitudinal follow-up)
No interventions assigned to this group
Type 2 diabetics, prevalent fractures
Postmenopausal women and men with T2DM, with prevalent fragility fractures
No interventions assigned to this group
Controls, no fractures
Age and sex-matched non-diabetic controls, without fragility fractures (longitudinal follow-up)
No interventions assigned to this group
Controls, prevalent fractures
Age and sex-matched non-diabetic controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* coexisting metabolic bone disease or comorbidities affecting bone health
* previous treatment with osteoporosis medication or intake of medications known to affect bone metabolism (e.g. steroids) within 6 months prior to enrolment
* thiazolidinedione use
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Schleswig-Holstein
OTHER
University Hospital, Basel, Switzerland
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Christian Meier
Prof. Dr. med.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian Meier, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Basel, Switzerland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine, Kantonsspital Bruderholz
Binningen, Basel-Landschaft, Switzerland
University Department of Internal Medicine, University Basel, Kantonsspital
Aarau, Canton of Aargau, Switzerland
Department of Internal Medicine, Kantonsspital Luzern
Lucerne, Canton of Lucerne, Switzerland
Department of Medicine, St. Anna Hospital Hirslanden
Lucerne, Canton of Lucerne, Switzerland
Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel
Basel, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sewing L, Potasso L, Baumann S, Schenk D, Gazozcu F, Lippuner K, Kraenzlin M, Zysset P, Meier C. Bone Microarchitecture and Strength in Long-Standing Type 1 Diabetes. J Bone Miner Res. 2022 May;37(5):837-847. doi: 10.1002/jbmr.4517. Epub 2022 Mar 8.
Vavanikunnel J, Sewing L, Triantafyllidou M, Steighardt A, Baumann S, Egger A, Grize L, Felix B, Kraenzlin M, Henzen C, Meier C. Determinants of Low Bone Turnover in Type 2 Diabetes-the Role of PTH. Calcif Tissue Int. 2022 Dec;111(6):587-596. doi: 10.1007/s00223-022-01022-7. Epub 2022 Oct 3.
Baumann S, Sewing L, Traechslin C, Verhagen-Kamerbeek W, Grize L, Kraenzlin M, Meier C. Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls. Calcif Tissue Int. 2025 Jan 7;116(1):25. doi: 10.1007/s00223-024-01338-6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EKNZ 2015-117
Identifier Type: -
Identifier Source: org_study_id